Rephonic
Artwork for Multiple Myeloma Hub

Multiple Myeloma Hub

Scientific Education Support
Multiple Myeloma
Bcma-Directed Therapies
CAR T-Cell Therapy
Cilta-Cel
Quality Of Life
Relapsed/refractory Multiple Myeloma
Elrenatumab
Clinical Trials
Bispecific Antibodies
Belantamab Mafodotin
Patient-Reported Outcomes
Teclistomab
Magestek-1 Trial
Cartitude-2
Cartitude-4
Relapsed and Refractory Multiple Myeloma
Daratumumab
Cytokine Release Syndrome
MRD
Smoldering Multiple Myeloma

The Multiple Myeloma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in multiple myeloma. Our aim is to enhance knowledge in multiple myeloma, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.

Hosted on Acast. See acast.com/privacy for more information.... more

PublishesWeeklyEpisodes90Founded6 years ago
Number of ListenersCategory
Education

Listen to this Podcast

Artwork for Multiple Myeloma Hub

Latest Episodes

The Multiple Myeloma Hub spoke with Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US. We asked, What’s on the horizon for the treatment of relapsed/refractory multiple myeloma (MM) in 2026?

In this interview, Lonial provides a... more

The Multiple Myeloma Hub spoke with Paul Richardson, Dana-Farber Cancer Institute, Boston, US. We asked about the emerging role of cereblon E3 ligase modulators (CELMoDs) in newly diagnosed multiple myeloma (NDMM) and high-risk smoldering multiple my... more

The Multiple Myeloma Hub spoke with Paul Richardson, Dana-Farber Cancer Institute, Boston, US. We asked about cereblon E3 ligase modulators (CELMoDs) for the treatment of relapsed/refractory multiple myeloma (RRMM).

During this interview, Richardso... more

The Multiple Myeloma Hub spoke with Paul Richardson, Dana-Farber Cancer Institute, Boston, US. We asked about the mechanism of action and immunomodulatory activity of cereblon E3 ligase modulators (CELMoDs) in multiple myeloma.

During this intervie... more

On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. During the symposium, Rakesh Popat chaired a panel discussion featuring patient... more

On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. During the symposium, Hang Quach, St Vincent’s Hospital Melbourne and Universit... more

On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. During the symposium, Fredrik Schjesvold, Oslo University Hospital, Oslo, NO, p... more

On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. During the symposium, Rakesh Popat, University College Hospital, London, UK, de... more

Key Facts

Accepts Guests
Accepts Sponsors
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

The Myeloma Minutes
The Myeloma MinutesDr Jam Kothari & Dr Sally Moore
ASCO Daily News
ASCO Daily NewsAmerican Society of Clinical Oncology (ASCO)
Economist Podcasts
Economist PodcastsThe Economist

Recent Guests

Sagar Lonial
Dr. Sagar Lonial from the Winship Cancer Institute of Emory University
Winship Cancer Institute of Emory University
Episode: What’s on the horizon for relapsed/refractory MM in 2026?
Paul Richardson
Director of Clinical Research and Clinical Program Leader, Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute; RJ Corman Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Episode: CELMoDs: Mechanism of action and immunomodulatory activity in MM
Rakesh Popat
Guest expert discussing QoL considerations in MM
University College Hospital, London (UK)
Episode: Quality-of-life considerations with BCMA‑directed therapies for MM
Maria Victoria Mateos
Professor and expert discussing BCMA-directed therapies in multiple myeloma
Episode: Symposium | Future directions with novel and established BCMA-DT in the MM treatment paradigm
Dr. Paul Richardson
Clinical program leader and director of clinical research at Dana-Farber Cancer Institute; RJ. Corman Professor of Medicine at Harvard Medical School
Dana-Farber Cancer Institute; Harvard Medical School
Episode: How might the clinical development of CELMoDs impact the treatment paradigm for MM?
Ravi Vij
From Washington University in St. Louis; discussing combination regimens with bi-specifics in RRMM
Washington University in St. Louis
Episode: What combination regimens including BiTEs are being evaluated for the treatment of RRMM?
Peter Forsberg
Dr. Peter Forsberg from the Colorado Blood Cancer Institute
Colorado Blood Cancer Institute
Episode: How can neurotoxicity associated with CAR T-cell therapy in MM be managed?
Shaji Kumar
Hematologist at Mayo Clinic
Mayo Clinic
Episode: What is the rationale for early intervention in high-risk smoldering MM?
Hang Quach
Hematologist at St Vincent's Hospital Melbourne and University of Melbourne
St Vincent's Hospital Melbourne; University of Melbourne
Episode: How are BCMA-directed bispecific antibodies currently utilized in real-world practice for MM?

Host

Marc-Andrea Bärtsch
Host of the session and presenter introducing BCMA targeting principles

Talking Points

Recent interactions between the hosts and their guests.

MRD in MM: Implications for clinical practice and trial design
Q: How should sustained MRD negativity influence trial design compared to single-time-point MRD?
Sustained MRD negativity is likely to be a more reliable predictor of long-term outcomes; future trials should emphasize longitudinal MRD assessments, include longer follow-up, and consider stratification by risk to interpret MRD data more accurately.
CAR T-cell therapies in clinical practice
Q: What is the next step in extremely high-risk patients?
Perhaps starting to combine immunotherapies with a CAR T-cell product for those patients.
Symposium | The next wave of immune-based therapies: What you need to know in relapsed/refractory multiple myeloma
Q: What are the key considerations when selecting between BCMA GPRC5D or FCRH5 targeted therapies?
Access to therapies and side effect management are crucial, with BCMA therapies currently having more data and easier access for patients.
Symposium | The next wave of immune-based therapies: What you need to know in relapsed/refractory multiple myeloma
Q: What biomarkers do you think are showing the most promise for tracking resistance to new wave immunotherapies?
The key biomarkers involve understanding the antigens expressed by patients and the level of mutations, which affect their response to therapies.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About Multiple Myeloma Hub

What is Multiple Myeloma Hub about and what kind of topics does it cover?

The series centers on multiple myeloma with a strong emphasis on BCMA-directed therapies, CAR T-cell approaches, and CELMoDs, alongside real-world practice considerations such as dosing strategies, toxicity management, quality of life, and access to innovative treatments. Episodes frequently feature leading clinicians and researchers discussing pivotal trials, emerging data, and practical implications for frontline and relapsed settings. A notable strength is the balance between mechanistic explanations, clinical data interpretation, and pragmatic guidance for clinicians, patients, and health systems, including real-world adaptations and sequencing questions for evolving therapies.

Where can I find podcast stats for Multiple Myeloma Hub?

Rephonic provides a wide range of podcast stats for Multiple Myeloma Hub. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to Multiple Myeloma Hub and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does Multiple Myeloma Hub get?

Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for Multiple Myeloma Hub, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for Multiple Myeloma Hub?

Rephonic provides comprehensive predictive audience data for Multiple Myeloma Hub, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does Multiple Myeloma Hub have?

To see how many followers or subscribers Multiple Myeloma Hub has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to Multiple Myeloma Hub?

These podcasts share a similar audience with Multiple Myeloma Hub:

1. The Myeloma Minutes
2. ASCO Daily News
3. Hematologic Oncology Update
4. The Readout Loud
5. Economist Podcasts

How many episodes of Multiple Myeloma Hub are there?

Multiple Myeloma Hub launched 6 years ago and published 90 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact Multiple Myeloma Hub?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for Multiple Myeloma Hub?

Rephonic pulls ratings and reviews for Multiple Myeloma Hub from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for Multiple Myeloma Hub?

Rephonic provides full transcripts for episodes of Multiple Myeloma Hub. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on Multiple Myeloma Hub?

Recent guests on Multiple Myeloma Hub include:

1. Sagar Lonial
2. Paul Richardson
3. Rakesh Popat
4. Maria Victoria Mateos
5. Dr. Paul Richardson
6. Ravi Vij
7. Peter Forsberg
8. Shaji Kumar

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days